Merck is Very Much a No Go - Avis employé Data Research Scientist Merck

1,0
28 févr. 2016
Recommande
Approbation du PDG
Perspective commerciale

Avantages

A few good people remain. Company benefits are average or above, other than tuition reimbursement which now is inadequate to earn a MS.

Inconvénients

Very much a dying company. Astonishingly bad esprit de corps, much worse now than when I joined over a decade ago. In the past 3 years, 90% of R&D talent has left the company or transferred to other divisions. Upper management are trying to convert all the remaining R&D and IT tasks into mechanized processes to then outsource them (supposedly saving money). All corporate initiative focuses either on saving money or on promoting Keytruda.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout